

PEER-REVIEW REPORT

Name of journal: *World Journal of Psychiatry*

Manuscript NO: 64584

Title: Newer antipsychotics: brexpiprazole, cariprazine, and lumateperone: a pledge or another unkept promise?

Reviewer's code: 02445209

Position: Editorial Board

Academic degree: N/A, MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Czech Republic

Author's Country/Territory: United States

Manuscript submission date: 2021-02-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-20 15:58

Reviewer performed review: 2021-06-25 06:10

Review time: 4 Days and 14 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Dear authors, I have a few comments on your manuscript: - On the page 11, the row 3 from below, trial ITI-007-303 you write on "standard of care medication". Would you describe this medication in a more detail? - Similarly, on the page 12, the rows 7 and 8 from above - trial ITI-007-303 - Part 2 your write on "the primary antipsychotic medication". A more comprehensive description of this medication would be better. - Conclusions: In the last sentence, you write about particular patient groups in which the newer antipsychotics may be beneficial. Which patient groups do you expect to profit from the new antipsychotics (brexpiprazole, cariprazine and lumateperone) and why?

The reviewer